[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its ...

Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

(FierceBiotech) Aromatase inhibitors and recombinant human growth hormone in combination significantly boosted adult height in adolescent boys with idiopathic short stature. (Journal of Clinical ...

It took almost a decade for Aliza Lynch to confirm she had endometriosis despite living with crippling pain that was so bad she would faint and vomit for a week every month.

Breast health, including breast cancer early detection and prevention, assessing and managing breast skin changes, and premature breast development ...

LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

Truqap can be used in patients whose disease has progressed despite prior endocrine therapy with a CDK 4/6 inhibitor and an aromatase inhibitor, according to a newly published guidance document.